These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

713 related articles for article (PubMed ID: 27898521)

  • 1. Pathogenesis and heterogeneity of ovarian cancer.
    Kroeger PT; Drapkin R
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):26-34. PubMed ID: 27898521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.
    Karst AM; Jones PM; Vena N; Ligon AH; Liu JF; Hirsch MS; Etemadmoghadam D; Bowtell DD; Drapkin R
    Cancer Res; 2014 Feb; 74(4):1141-52. PubMed ID: 24366882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
    Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whence High-Grade Serous Ovarian Cancer.
    Kohn EC; Ivy SP
    Am Soc Clin Oncol Educ Book; 2017; 37():443-448. PubMed ID: 28561656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
    Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
    J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?
    Klotz DM; Wimberger P
    Arch Gynecol Obstet; 2017 Dec; 296(6):1055-1062. PubMed ID: 28940023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker Assessment of HR Deficiency, Tumor
    Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
    Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
    Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
    J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer.
    Coan M; Rampioni Vinciguerra GL; Cesaratto L; Gardenal E; Bianchet R; Dassi E; Vecchione A; Baldassarre G; Spizzo R; Nicoloso MS
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic lethality between CCNE1 amplification and loss of BRCA1.
    Etemadmoghadam D; Weir BA; Au-Yeung G; Alsop K; Mitchell G; George J; ; Davis S; D'Andrea AD; Simpson K; Hahn WC; Bowtell DD
    Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19489-94. PubMed ID: 24218601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two different, mutually exclusively distributed,
    Sukhbaatar N; Bachmayr-Heyda A; Auer K; Aust S; Deycmar S; Horvat R; Pils D
    Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.
    Yan S; Frank D; Son J; Hannan KM; Hannan RD; Chan KT; Pearson RB; Sanij E
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
    Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
    Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
    Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
    J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
    Lepage CC; Palmer MCL; Farrell AC; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
    Br J Cancer; 2021 May; 124(10):1699-1710. PubMed ID: 33731859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
    Mittempergher L
    Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.